Tags

Type your tag names separated by a space and hit enter

[High purity ryanodine for in vitro diagnosis of malignant hyperthermia].

Abstract

OBJECTIVE AND STUDY DESIGN

The identification of disposition for malignant hyperthermia (MH) is performed by the halothane-caffeine contracture test in skeletal muscle. However, testing currently renders about 14% of the patients MH equivocal (MHE). To reduce this number the "ryanodine contracture test" has been proposed in addition to the established procedure. As all ryanodine preparations used until now are combinations of ryanodine and dehydroryanodine, we investigate in this study the effects of the now available high-purity ryanodine (HPR) in concentrations of 2,5 and 10 mumol/l.

RESULTS

With all concentrations contractures appeared significantly earlier in MHS (malignant hyperthermia susceptible) than in MHN (malignant hyperthermia non-susceptible). However, only at 2 mumol/l a time overlap between both groups was not observed. By defining a time interval for MHS and MHN, three of the MHE patients could be assigned to MHS and three to MHN following their ryanodine-induced contractures.

CONCLUSION

The ryanodine contracture test should be added to the current diagnostics of malignant hyperthermia.

Authors+Show Affiliations

Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf, Hamburg.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

ger

PubMed ID

8297948

Citation

Wappler, F, et al. "[High Purity Ryanodine for in Vitro Diagnosis of Malignant Hyperthermia]." Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, vol. 28, no. 7, 1993, pp. 427-31.
Wappler F, Roewer N, Lenzen C, et al. [High purity ryanodine for in vitro diagnosis of malignant hyperthermia]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1993;28(7):427-31.
Wappler, F., Roewer, N., Lenzen, C., Scholz, J., Steinfath, M., Rumberger, R., & Schulte am Esch, J. (1993). [High purity ryanodine for in vitro diagnosis of malignant hyperthermia]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 28(7), 427-31.
Wappler F, et al. [High Purity Ryanodine for in Vitro Diagnosis of Malignant Hyperthermia]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1993;28(7):427-31. PubMed PMID: 8297948.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [High purity ryanodine for in vitro diagnosis of malignant hyperthermia]. AU - Wappler,F, AU - Roewer,N, AU - Lenzen,C, AU - Scholz,J, AU - Steinfath,M, AU - Rumberger,R, AU - Schulte am Esch,J, PY - 1993/11/1/pubmed PY - 1993/11/1/medline PY - 1993/11/1/entrez SP - 427 EP - 31 JF - Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS JO - Anasthesiol Intensivmed Notfallmed Schmerzther VL - 28 IS - 7 N2 - OBJECTIVE AND STUDY DESIGN: The identification of disposition for malignant hyperthermia (MH) is performed by the halothane-caffeine contracture test in skeletal muscle. However, testing currently renders about 14% of the patients MH equivocal (MHE). To reduce this number the "ryanodine contracture test" has been proposed in addition to the established procedure. As all ryanodine preparations used until now are combinations of ryanodine and dehydroryanodine, we investigate in this study the effects of the now available high-purity ryanodine (HPR) in concentrations of 2,5 and 10 mumol/l. RESULTS: With all concentrations contractures appeared significantly earlier in MHS (malignant hyperthermia susceptible) than in MHN (malignant hyperthermia non-susceptible). However, only at 2 mumol/l a time overlap between both groups was not observed. By defining a time interval for MHS and MHN, three of the MHE patients could be assigned to MHS and three to MHN following their ryanodine-induced contractures. CONCLUSION: The ryanodine contracture test should be added to the current diagnostics of malignant hyperthermia. SN - 0939-2661 UR - https://www.unboundmedicine.com/medline/citation/8297948/[High_purity_ryanodine_for_in_vitro_diagnosis_of_malignant_hyperthermia]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-998957 DB - PRIME DP - Unbound Medicine ER -